Company Active LTD

Company profile

Phoenix DX Ltd

Hand-Held PCR Tests | UK | Phoenix DX

Phoenix DX are the UK-based creators of Molerumi, a device for performing hand-held PCR tests. Find out more about our innovative new product.

CRN
08828924
Founded
2014
Age
12

Overview

Legal name
PHOENIX DX LTD
Region
London
Registered address
C/O QUANTUMA ADVISORY LIMITED, 7TH FLOOR
20 ST. ANDREW STREET
LONDON
EC4A 3AG
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

1 level 1 ultimate controller
1
Company Active LTD
Phoenix DX Ltd
CRN 08828924
2
Direct and ultimate controller
02102499
CRN 02102499

Company events

Reference milestones and recent Companies House filing stream events.

6 events
20 Sep
2024

Change Registered Office Address Company With Date Old Address New Address

Address

AD01 | Transaction MzQzNTY0MjI5MmFkaXF6a2N4 | Paper/PDF filed

Published 21 Sep 2024 06:28

30 Sep
2023

Accounts due

Accounts Due

Next accounts due date

19 Aug
2023

Confirmation statement due

Confirmation Due

Next confirmation statement due date

05 Aug
2022

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2021

Accounts filed

Accounts

Last accounts made up date

02 Jan
2014

Incorporated

Inception

Company registered at Companies House

Public funding

5 awards
First funded
2015
Funded years
2015, 2016, 2017, 2018
Age at first award
1 years

Projects

2018 Collaborative R&D Lead participant

Feasibility assessment of rapid identification (R-ID) technology for point of care detection of urinary tract infections and drug-resistance markers

1 Nov 2018 to 31 Oct 2019

Awarded
£34,271
Total cost £48,958

"The proposed project aims to evaluate the technical, clinical, and commercial value of LIG Biowise's developed technology (R-ID) to assist diagnosis and management of urine tract infections (UTI) at the point of care (POC), where high proportion of UTI affected patients is treated. Urinary tract infections (UTI) are very common infections, affecting arou...

2017 Feasibility Studies Lead participant

Respiratory Infection Detection (R-ID) assay

1 Aug 2017 to 31 Jul 2018

Awarded
£82,582
Total cost £117,974

Infectious diseases are one of the major causes of global morbidity and mortality, resulting in 16.2% of deaths per year. Currently, there is no fast diagnostic tool available to detect and identify the different pathogens responsible for the most common infections, which leads to unnecessary prescription of antibiotics and the subsequent development of d...

2017 Feasibility Studies Lead participant

Magnetic Antimicrobial Peptide-based (MAP) DNA Extraction Kit

1 Jun 2017 to 31 May 2018

Awarded
£56,279
Total cost £80,398

The accuracy and sensitivity of a molecular diagnostic method is dependent of the efficient extraction of nucleic acids and absence of amplification inhibitors in the reaction mixture. Bacterial DNA/RNA extraction usually requires enzymatic, physical or chemical cell lysis, which is especially critical when working with Gram + bacteria. DNA/RNA purificati...

2016 GRD Proof of Market Lead participant

Spiky Ag Nanoparticles for Super-Efficient Antibacterial Surface Coatings

1 Apr 2016 to 31 Jul 2016

Awarded
£24,844
Total cost £41,407

Silver (Ag) nanoparticles have gained popularity for use in medical devices, washing powders and water treatments largely due to the emergence of resistant bacteria (superbugs) and the resultant reduction in the effective number of available treatments. However concerns have been raised due to the high concentrations required including the lack of availab...

2015 GRD Proof of Market Lead participant

Biodegradable Antibacterial Nanoparticles: The Next Generation of Antibiotics

1 Sep 2015 to 31 Dec 2015

Awarded
£24,835
Total cost £41,392

Nosocomial infections caused by multidrug-resistant microorganisms such as MRSA and P.aeruginosa are observed frequently in hospital settings; resulting in serious public health problems. The most pressing concern is that they are becoming resistant to almost all antibiotics available at the present time. Nanomedicine offers new possibilities including fe...

Product types

Collaborative R&D Feasibility Studies GRD Proof of Market